AI Summary
The text explains that two recent studies have revealed how immunotherapies targeting the immune checkpoints PD1 and LAG3 collaborate to enhance T cell responses in melanoma. The research demonstrates why combining therapies that target both checkpoints can be more beneficial for melanoma patients than using treatments that target PD1 alone. This discovery sheds light on the mechanisms behind improved outcomes with combination therapies.
Two recent studies uncover how immunotherapies targeting the immune checkpoints PD1 and LAG3 work together to activate immune responses. The findings shed light on why combination therapies targeting both checkpoints can improve outcomes for melanoma patients compared to monotherapies targeting only PD1.